Saltar al contenido
Merck
  • Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.

Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.

Oncoimmunology (2015-09-26)
Wendy Wj Unger, Christian T Mayer, Steef Engels, Christina Hesse, Maurizio Perdicchio, Franz Puttur, Ingeborg Streng-Ouwehand, Manja Litjens, Hakan Kalay, Luciana Berod, Tim Sparwasser, Yvette van Kooyk
PMID26405564
RESUMEN

Therapeutic vaccinations against cancer are still largely ineffective. Major caveats are inefficient delivery of tumor antigens to dendritic cells (DCs) and excessive immune suppression by

MATERIALES
Referencia del producto
Marca
Descripción del producto
P8139
Sigma-Aldrich
Forbol 12-miristato 13-acetato, ≥99% (TLC), film or powder
D9542
Sigma-Aldrich
DAPI, for nucleic acid staining
P1585
Sigma-Aldrich
PMA, for use in molecular biology applications, ≥99% (HPLC)
W292907
Sigma-Aldrich
Alcohol isopropílico, ≥99.7%, FCC, FG
59304
Sigma-Aldrich
2-Propanol, BioUltra, for molecular biology, ≥99.5% (GC)
B7651
Sigma-Aldrich
Brefeldin A, from Penicillium brefeldianum, ≥99% (HPLC and TLC)
733458
Sigma-Aldrich
2-Propanol, electronic grade, 99.999% trace metals basis
79346
Sigma-Aldrich
Forbol 12-miristato 13-acetato, synthetic, ≥98.0% (TLC)
B6542
Sigma-Aldrich
Brefeldin A, ≥99% (HPLC and TLC), BioXtra, for molecular biology
278475
Sigma-Aldrich
2-Propanol, anhydrous, 99.5%
I9516
Sigma-Aldrich
2-Propanol, for molecular biology, BioReagent, ≥99.5%
B5936
Sigma-Aldrich
Brefeldin A, from Penicillium brefeldianum, Ready Made Solution, 10 mg/mL in DMSO
E2028
Sigma-Aldrich
Ethidium bromide monoazide, ≥95% (HPLC), solid